This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

Switching Drug Class After Initial SSRI Failure

Jeffrey E. Kelsey

Published: July 15, 1997

Article Abstract

Letter to the Editor

Sir: The report by Joffe et al. underscores an important issue
for the practicing psychiatrist, namely, the appropriate next
step for the nonresponder to a serotonin selective reuptake inhibitor
(SSRI) antidepressant. Their data from an open-label,
non-placebo-controlled database review showed that 51% of
patients responded to a second SSRI after experiencing lack of
efficacy with their initial SSRI. This response represents an important
question to be assessed in controlled trials, and the authors
acknowledge that the lack of a placebo-controlled design
limits their conclusions.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 58

Quick Links: